GENEVA — Health authorities and clinical researchers today published landmark Phase 3 trial results demonstrating that personalized mRNA cancer vaccines, when administered alongside standard immunotherapy, significantly reduce the risk of disease recurrence and death in patients treated for high-risk melanoma and non-small cell lung cancer. The definitive data marks a critical transition in oncology, moving individualized immunotherapies from experimental clinical trials toward broader integration into routine hospital care.
The multi-center study, which tracked over 1,000 patients across 25 countries over a three-year observation period, evaluated a custom neoantigen therapy designed to train the immune system to recognize unique genetic mutations present in a patient’s specific tumor cells. According to trial coordinators, patients who received the custom vaccine in combination with immune checkpoint inhibitors demonstrated a 49 percent reduction in the risk of cancer recurrence or mortality compared to those who received immunotherapy alone.
Unlike traditional preventive vaccines aimed at infectious pathogens, personalized mRNA cancer therapies are therapeutic treatments manufactured individually for each patient. Following surgical tumor removal, laboratory teams perform deep genetic sequencing on the tissue to identify distinct surface proteins, known as neoantigens, that are most likely to trigger an immune response. A bespoke mRNA sequence is then synthesized to instruct the patient’s cellular machinery to generate those specific targets, mobilizing T-cells to identify and eliminate lingering microscopic cancer cells.
Oncologists leading the study highlighted the sustained immune memory observed in participants, noting that combination therapy effectively prevented late-stage rel
